Esophageal Cancer Clinical Trial
Official title:
Randomized Clinical Trial of Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy
The clinical value of intraoperative nerve monitoring (IONM) in thoracoscopic esophagectomy remains uncertain. The aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their morbidity following thoracoscopic esophagectomy.
Recurrent laryngeal nerves (RLN) lymph nodes are the most common metastatic areas in esophageal squamous carcinoma. It is a clinical challenge to reduce high incidence of RLN injury rate result from routine dissection of RLN lymph nodes. Thoracoscopic approach may provide a clear operative field and potentially less invasive surgery. But there are still high RLN injury rate only depending on visualization of thoracoscopy. The use of intraoperative nerve monitoring (IONM) was shown very helpful to identify the RLN and associated with a reduction of RLN injury rate in thyroidectomy. However, there is no solid clinical evidence about the effectiveness of utility of IONM in thoracoscopic esophagectomy. Thus, the aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their morbidity following thoracoscopic esophagectomy. ;
NCT number | NCT05199168 |
Study type | Interventional |
Source | Tianjin Medical University Cancer Institute and Hospital |
Contact | Hongjing Jiang, MD. Ph.D. |
Phone | 02223340123 |
[email protected] | |
Status | Recruiting |
Phase | N/A |
Start date | February 1, 2022 |
Completion date | July 1, 2024 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT01404156 -
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
|
Phase 2/Phase 3 | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 | |
Withdrawn |
NCT02491372 -
A Pilot Study of the Effectiveness of Acceptance and Commitment Therapy With a Post-Upper GI Cancer Population
|
N/A | |
Recruiting |
NCT02454790 -
Standard Follow-Up Program (SFP) for Patients With Esophageal Cancer
|
N/A | |
Recruiting |
NCT01691664 -
Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT01766349 -
Effect of CCRT on Respiratory Performance and Functional Capacity in Esophagus Cancer Patients
|
N/A |